Related Experiment Videos
High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia
1Division of Medicine, Hadassah University Hospital, Jerusalem, Isreal.
Insights
This study evaluated long-term fluvastatin and bezafibrate use in severe familial hypercholesterolemia. Higher doses improved low-density lipoprotein cholesterol (LDL-C) levels in non-responders.
Area of Science:
- Cardiology
- Pharmacology
- Genetics
Background:
- Familial hypercholesterolemia (FH) is a genetic disorder causing high LDL-C.
- Previous treatments with fluvastatin and bezafibrate failed to reach target LDL-C levels in some severe FH patients.
- Long-term efficacy and safety of intensified lipid-lowering therapy are crucial for managing FH.
Purpose of the Study:
- To assess the long-term efficacy and safety of escalating doses of fluvastatin, alone or with bezafibrate, in severe FH patients.
- To evaluate treatment adjustments in patients who did not achieve target low-density lipoprotein cholesterol (LDL-C) levels previously.
- To determine optimal combination therapy for severe familial hypercholesterolemia.
Main Methods:
- Open-label study with 3 treatment periods involving escalating fluvastatin and bezafibrate doses.
- Patients received fluvastatin (40-800 mg/day) and bezafibrate (200-400 mg/day) based on prior response.
- Exclusion criteria included serious adverse events or liver/kidney function impairment.
Main Results:
- The study involved escalating fluvastatin and bezafibrate dosages in severe FH patients.
- Lipid profiles were monitored regularly, with standard physical and laboratory evaluations.
- Adverse events were systematically recorded throughout the study.
Conclusions:
- Escalating fluvastatin and bezafibrate doses may improve LDL-C in severe FH patients unresponsive to standard therapy.
- Long-term management of severe FH requires individualized, intensified treatment strategies.
- Further research is needed to confirm long-term outcomes and safety profiles.
Abstract:
This study assessed the long-term use of fluvastatin, alone or in combination with bezafibrate, in patients with severe familial hypercholesterolemia who, in a previous study, did not achieve target levels (European Atherosclerosis Society) of low density lipoprotein cholesterol (LDL-C) with fluvastatin at 60 mg/day plus bezafibrate 200 mg/day, with or without cholestyramine (CME) at 8 g/day. This open-label study comprised 3 periods: period I, 6 weeks of fluvastatin at 40 mg twice daily (at breakfast and at bedtime); period II, fluvastatin at 80 mg/day (40 mg at breakfast, 40 mg at bedtime), and bezafibrate at 200 mg/day (at lunchtime) for 6 weeks in patients not achieving LDL-C target levels; and period III, force-titration of fluvastatin to 800 mg/day (as in period II) and bezafibrate at 400 mg/day (slow release) in patients receiving combination treatment. Patients were excluded if, during the previous study, they had experienced a serious drug-related adverse event or deterioration in liver or kidney function (liver enzymes > 3 times upper limit of normal). The standard physical and laboratory evaluations were performed at regular intervals. Lipid profiles were determined from 12-hour fasting blood samples. All adverse events occurring or worsening during the study, whether spontaneously reported or elicited by questioning, and regardless of relationship to study medication, were recorded.(ABSTRACT TRUNCATED AT 250 WORDS)